29 October 2026 Quarterly Activities Report and Appendix 4C For the period ended 30 September 2026 Key Milestones Achieved as Patrys Successfully Completes Cohort 1 Dosing in RLS-2202 Phase 1a Trial Highlights: • Human Research Ethics Committee (HREC) approval secured and first participants dosed...